InvestorsHub Logo
Followers 43
Posts 15829
Boards Moderated 0
Alias Born 09/16/2012

Re: None

Tuesday, 05/21/2024 10:04:04 AM

Tuesday, May 21, 2024 10:04:04 AM

Post# of 700840
2011.

>>DCVax® immune therapies for a broad range of cancers (including prostate, brain, ovarian and others) hold the promise, based on available data to date, of being cost effective and priced below other immune therapies while still providing substantial profit margins for the Company and longer survival for patients.

https://www.biospace.com/article/releases/northwest-biotherapeutics-highlights-cost-effectiveness-of-dcvax-in-view-of-recent-immunotherapy-pricing-concerns-408411/
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News